Review on the Therapeutic Potential of Curcumin and its Derivatives on Glioma Biology

Neurochem Res. 2022 Oct;47(10):2936-2953. doi: 10.1007/s11064-022-03666-1. Epub 2022 Jul 5.

Abstract

Gliomas are common and aggressive brain tumors that carry a poor prognosis. The current multimodal therapeutic option for glioma includes surgery subsequently temozolomide chemotherapy and/or radiation; but gliomas are often associated with multidrug resistance, intensive adverse events, and tumor relapse. Thus, novel interventions that can enhance successful chemo-prevention and overcome therapeutic resistance are urgently needed. Phytochemicals have several biological properties with multi-target sites and relatively limited degrees of toxicity. Curcumin is a natural polyphenolic compound with several anti-tumor effects which potentially inhibit tumor growth, development, proliferation, invasion, dissemination, and angiogenesis in different human malignancies. Experimental model studies have demonstrated that curcumin attenuates glioma cell viability by G2/M cell cycle arrest, apoptosis, induction of autophagy, gene expression alteration, and disruption of multi-molecular pathways. Moreover, curcumin has been reported to re-sensitize cancer to chemotherapeutics as well as augment the effect of radiotherapy on glioma cells. In this review, we have provided an update on the in vitro and in vivo effects of curcumin-based therapy on gliomas. We have also discussed the use of curcumin in combination therapies, its effectiveness on drug-resistant cells, and new formulations of curcumin in the treatment of gliomas.

Keywords: Apoptosis; Brain tumor; PI3K; Temozolomide; Turmeric.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Biology
  • Brain Neoplasms* / pathology
  • Cell Line, Tumor
  • Curcumin* / pharmacology
  • Curcumin* / therapeutic use
  • Glioma* / metabolism
  • Humans
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Curcumin